Despite the current use of 5-AzaC and 5-AzaDC in the clinic and the development of more stable and deamination-resistant nucleoside DNMT inhibitors, their lack of specificity, poor bioavailability, instability, and toxicity are still major concerns for their widespread use in cancer treatment. Here, DNMT1 is linked to cancer.